The survival rates of patients with esophageal and gastric cancers have improved. However, many survivors continue to ...

BERLIN -- In a global phase III trial, the addition of durvalumab (Imfinzi) to standard chemotherapy given before and after surgery led to a statistically significant and "clinically meaningful" ...

Gastric cancer remains a major global health challenge, ranking among the leading causes of cancer-related mortality worldwide. Its incidence varies markedly by region, with the highest rates reported ...

Tevimbra/Ziihera as a first-line treatment for advanced cancers of the stomach, gastroesophageal junction, and esophagus. The ...

Data on disease stage at presentation and treatment outcomes were obtained from the King Hussein Cancer Center registry. Patients were staged according to the US SEER staging system, which classifies ...

PolyPEPI1018 Cancer Vaccine and TAS-102 for Patients With Advanced, Chemo-Refractory, Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib Nonrandomized Study Using SEER 22 data, we analyzed ...

Advanced gastric cancer remains one of the deadliest malignancies, with a 5-year overall survival rate below 10%. In recent years, combining chemotherapy with PD-1 or PD-L1 inhibitors has become ...

SALT LAKE CITY — The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people ...